Brief: Argent BioPharma Reports Agreement For Malta Manufacturing Facility
12/03/2025 01:14
March 12 (Reuters) - Argent BioPharma RGT.AX: EXCLUSIVE AGREEMENT FOR MALTA MANUFACTURING FACILITY-RGT.AX UNDER TERM SHEET, ARGENT BIOPHARMA MUST RECEIVE A MINIMUM CONSIDERATION OF US$1 MILLION UNDER TERM SHEET, ARGENT BIOPHARMA MUST RECEIVE A MINIMUM CONSIDERATION OF US$1 MILLION Further company coverage: RGT.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Argent BioPharma
See all newsBrief: Argent Biopharma Executes Global Licence For Non-Core Cannabis Genetics
Brief: Argent Biopharma Files Provisional US Patent On Immune Modulation And Longevity
Australia's Argent BioPharma rises to over 1-month high on new licence agreement
Brief: Argent Biopharma Signs NLC Licence To Expand Antiviral Portfolio
Brief: Argent Biopharma Says FDA-CVM Established Inad File For Cannepil Veterinary Program